Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.46 |
| ▸ | F10 | P00742 | 5/20 | 0.44 |
| ▸ | ECE1 | P42892 | 5/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926868 | 0.90 | ABCB1 (0.45) | ABCB1F10ECE1FSCN1MAOB | |
| SCHEMBL3157047 | 0.86 | ABCB1 (0.48) | ABCB1F10ECE1ROCK2CCR2 | |
| SCHEMBL3157966 | 0.86 | ABCB1 (0.48) | ABCB1F10ECE1ROCK2CCR2 | |
| SCHEMBL1052136 | 0.86 | F10 (0.42) | ABCB1F10ECE1FSCN1MAOB | |
| SCHEMBL926723 | 0.82 | F10 (0.43) | ABCB1F10ECE1FSCN1MAOB | |
| SCHEMBL2898536 | 0.81 | ABCB1 (0.47) | ABCB1F10ECE1 | |
| SCHEMBL1053385 | 0.80 | F10 (0.46) | ABCB1F10ECE1FSCN1MAOB | |
| SCHEMBL926660 | 0.80 | MAOB (0.47) | ABCB1F10ECE1FSCN1MAOB | |
| SCHEMBL1049583 | 0.80 | F10 (0.41) | ABCB1F10ECE1FSCN1MAOB | |
| SCHEMBL2898360 | 0.80 | SCD (0.45) | ABCB1F10ECE1MAOBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235015-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-24 | — | — | EP | claimed |
| US-8354425-B2 | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | claimed |
| CN-101977911-A | Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-02-16 | — | — | CN | claimed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| EP-2235015-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-8354425-B2 | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| CN-101977911-A | Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-02-16 | — | — | CN | disclosed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ZYX, XDH, ZFX | ABCB1 777/4885F10 1361/4885ECE1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.